GE Healthcare, announced a new worldwide distribution/sales representation agreement with InSightec Image Guided Treatment Ltd. for the sales and marketing of ExAblate 2000, the first MRI-guided, focused ultrasound system designed to non-invasively treat uterine fibroids.
Under the terms of the agreement, GE, a minority shareholder in InSightec, will have exclusive worldwide distribution rights for ExAblate 2000 with the exception of Japan and Russia where InSightec has existing distributors and representatives. InSightec and GE also will collaborate on research and development and marketing. The agreement is for five years, effective immediately.
ExAblate 2000 is a non-invasive therapy system that combines MRI with highly focused ultrasound to thermally ablate tumors in the body. It is only compatible with GE's MR systems. ExAblate 2000, in combination with GE's Signa MR system, allows physicians to locate and measure the size of a tumor before precisely ablating it through concentrated sound wave energy without incision. It also gives doctors real-time therapy planning capabilities through tools that monitor thermal effects, ensuring the procedure's efficacy and the patient's safety.